[HTML][HTML] Outpatient and inpatient anticoagulation therapy and the risk for hospital admission and death among COVID-19 patients
Abstract Background Coronavirus disease 2019 (COVID-19) is associated with a
hypercoagulable state. Limited data exist informing the relationship between anticoagulation …
hypercoagulable state. Limited data exist informing the relationship between anticoagulation …
[HTML][HTML] Anticoagulation Prior to COVID-19 Infection Has No Impact on 6 Months Mortality: A Propensity Score–Matched Cohort Study
M Protasiewicz, K Reszka, W Kosowski… - Journal of Clinical …, 2022 - mdpi.com
The coronavirus disease 2019 (COVID-19) shows high incidence of thromboembolic events
in humans. In the present study, we aimed to evaluate if anticoagulation prior to COVID-19 …
in humans. In the present study, we aimed to evaluate if anticoagulation prior to COVID-19 …
Anticoagulation before hospitalization is a potential protective factor for COVID‐19: insight from a French multicenter cohort study
Background Coronavirus disease 2019 (COVID‐19) is a respiratory disease associated with
thrombotic outcomes with coagulation and endothelial disorders. Based on that, several …
thrombotic outcomes with coagulation and endothelial disorders. Based on that, several …
Association of anticoagulation dose and survival in hospitalized COVID‐19 patients: a retrospective propensity score‐weighted analysis
F Ionescu, I Jaiyesimi, I Petrescu… - European journal of …, 2021 - Wiley Online Library
Background Hypercoagulability may contribute to COVID‐19 pathogenicity. The role of
anticoagulation (AC) at therapeutic (tAC) or prophylactic doses (pAC) is unclear. Objectives …
anticoagulation (AC) at therapeutic (tAC) or prophylactic doses (pAC) is unclear. Objectives …
Anticoagulation and bleeding risk in patients with COVID-19
N Musoke, KB Lo, J Albano, E Peterson, R Bhargav… - Thrombosis research, 2020 - Elsevier
Background There is no current standardized approach to anticoagulation in patients with
Coronavirus Disease 2019 (COVID-19) while potential bleeding risks remain. Our study …
Coronavirus Disease 2019 (COVID-19) while potential bleeding risks remain. Our study …
Anticoagulation in COVID-19 patients–An updated systematic review and meta-analysis
S Reis, M Popp, S Schießer, MI Metzendorf… - Thrombosis …, 2022 - Elsevier
Background Thromboembolic events are common complications of COVID-19. Clinical study
results on safety and efficacy of anticoagulation in COVID-19 are controversial. Material and …
results on safety and efficacy of anticoagulation in COVID-19 are controversial. Material and …
Chronic therapeutic anticoagulation is associated with decreased thrombotic complications in SARS‐CoV‐2 infection
DJ Lachant, NA Lachant, P Kouides… - … of thrombosis and …, 2020 - Wiley Online Library
Background Thrombotic disease complicates severe SARS‐CoV‐2 infection and is
associated with increased morbidity and mortality. Various anticoagulation strategies have …
associated with increased morbidity and mortality. Various anticoagulation strategies have …
Impact of anticoagulation prior to COVID-19 infection: a propensity score–matched cohort study
D Tremblay, M Van Gerwen, M Alsen… - Blood, The Journal …, 2020 - ashpublications.org
Tremblay and colleagues asked whether patients receiving either routine anticoagulation or
antiplatelet therapy for existing conditions prior to becoming ill with COVID-19 have different …
antiplatelet therapy for existing conditions prior to becoming ill with COVID-19 have different …
Reduction in all-cause mortality in COVID-19 patients on chronic oral anticoagulation: a population-based propensity score matched study
Abstract Background Coronavirus disease 2019 (COVID-19) global pandemic has strikingly
high mortality rate with hypercoagulability state being part of the imputed mechanisms. We …
high mortality rate with hypercoagulability state being part of the imputed mechanisms. We …
Anticoagulation outcomes in hospitalized Covid‐19 patients: A systematic review and meta‐analysis of case‐control and cohort studies
Background: Coagulopathy and thromboembolic events are common in Covid‐19 patients
and are poor prognostic factors. Controversy exists regarding the potential of …
and are poor prognostic factors. Controversy exists regarding the potential of …